Navigation Links
Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
Date:3/23/2011

d clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.  

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.Contact: Company

Contact: Investor RelationsChristine Berni

Donald C. Weinberger/Diana Bittner (media)Director of Investor Relations

Wolfe Axelrod Weinberger Assoc. LLCAccess Pharmaceuticals, Inc.

(212) 370-4500(212) 786-6208
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
2. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
3. Mymetics Corporation Information to be Available Through Standard & Poors Market Access Program
4. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
5. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
6. Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
7. Former NASDAQ International President Among Execs Launching Firm to Access Global Markets
8. USDA Awards $1.5 Million to Expand Access to High-Quality Critical Care in Rural Communities
9. Stem Cell Sciences Signs Service Agreement With Pfizer to Provide Access to Proprietary Technologies and Methods
10. GeneNews provides Centocor access to its osteoarthritis program
11. Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 First antibacterial ... a truly novel class of anti-infective in ... a biopharmaceutical company developing a truly novel ... has secured £4.0m ($6.4m) to advance the ... a range of Gram-positive infections including  Clostridium ...
(Date:9/16/2014)... 2014 This report analyzes the worldwide markets for ... Hardware, and Biocontent. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... of World. Annual estimates and forecasts are provided for the ... provided for these markets. Market data and analytics are derived ...
(Date:9/16/2014)... film for radar domes have now refined the technology ... , The new work by Rice chemist James Tour ... to skyscrapers free of ice and fog while retaining ... technology was introduced this month in the American Chemical ... , The material is made of graphene nanoribbons, atom-thick ...
(Date:9/16/2014)... DURHAM, N.C. , Sept. 16, 2014 /PRNewswire-USNewswire/ ... and oldest entrepreneurial support organization in the country, ... Innovators Report . It ... North Carolina startups in ... sectors drew more global investment from a variety ...
Breaking Biology Technology:MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23Nanoribbon film keeps glass ice-free 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4
... by leading European authority on natural/ organic ... Oct. 6 /PRNewswire-FirstCall/ - Botaneco Specialty Ingredients,Inc. (Botaneco), ... that its second generation oleosome product, Hydresia(TM) G2, ... material, complying with,the standards for ecological and organic ...
... software and services company, today announced SPL for ... Documentum,s Documentum Compliance Manager (DCM) application. SPL ... solution and addresses the SPL Release 4 submission ... latest addition to Glemser,s family of pharmaceutical labeling ...
... contains many genes encoding proteins that are similar to those ... for only a small fraction the genome, and there are ... What are these sequences doing, and do we really need ... in Genome Research ( www.genome.org ), researchers have ...
Cached Biology Technology:Botaneco receives natural ingredient approval from ECOCERT(R) for Hydresia(TM) G2 2Botaneco receives natural ingredient approval from ECOCERT(R) for Hydresia(TM) G2 3Glemser Announces New Labeling Solution: SPL for DCM Addresses New SPL Release 4 Requirements 2Use it or lose it? Researchers investigate the dispensability of our DNA 2
(Date:9/17/2014)... MRSA and MSSA could be curbed by coating ... scaly surface of shark skin, according to research ... Resistance and Infection Control . , The study ... of human disease bacteria through touching, sneezes or ... of ridges formulated to resemble shark skin. The ...
(Date:9/16/2014)... (17 September, 2014)More than $100 trillion in cumulative ... annual carbon dioxide (CO2)a 40 percent reduction of ... if the world expands public transportation, walking and ... released by the University of California, Davis, and ... , Further, an estimated 1.4 million early ...
(Date:9/16/2014)... viruses that make us sick can take up residence ... sneeze, cough or other troublesome symptom, according to new ... Louis. , On average, healthy individuals carry about ... report online in BioMed Central Biology . The ... diversity of viruses in healthy people. , The ...
Breaking Biology News(10 mins):Sharks' skin has teeth in the fight against hospital superbugs 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5Healthy humans make nice homes for viruses 2Healthy humans make nice homes for viruses 3
... BETHLEHEM, PA, March 17, 2009 -- Lehigh University ... awarded a $1.8 million grant from the National ... and Other Communication Disorders for his research entitled ... grant will allow Burger to build upon the ...
... between food, nutrition science, and health outcomes have been ... individuals and populations is a new factor that enriches ... the rapidly emerging intersection of nutritional science and genomics ... issue of OMICS: A Journal of Integrative Biology ...
... papilloma virus (HPV)-infections can lead to cellular changes in ... cancer. Surgical treatment of these pre-stages gives an increased ... HPV-vaccine can prevent pre-stages of cervical cancer, it may ... Norwegian study has calculated the benefits of HPV-vaccination. ...
Cached Biology News:Lehigh researcher awarded $1.8 million NIH grant 2Lehigh researcher awarded $1.8 million NIH grant 3Nutrigenomics -- developing personalized diets for disease prevention -- part 2 just published in OMICS 2HPV vaccine may prevent preterm births 2
... screening, low melting point agarose where separation ... recommended for separation of nucleic acids less ... products. Micro ABgarose is also suited to ... blotting techniques. At a 3% concentration, Micro ...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
... Abpromise for all tested applications). ... derived from within residues 1 - 100 of ... is proprietary) (Peptide available as ... ID: 5453 Swiss Protein ...
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Biology Products: